KING OF PRUSSIA, Pa. — June 13, 2017 — “The Mind of God: Neuroscience, Faith, and a Search for the Soul,” authored by Dr. Jay Lombard, the co-founder of Genomind, is being published today by Harmony Books, an imprint of Penguin Random House.
The book is a cerebral journey into the depths of the mind to resolve some of the most riveting questions that lie at the intersection of science and spirituality, including the most pressing: Is there really a God?
Lombard serves as Chief Scientific Officer and Medical Director at Genomind, a personalized medicine company bringing innovation to mental health care through genetic testing. Clinicians use the results of Genomind’s Genecept Assay® to help reduce the time, expense and struggle of finding the right drugs and other treatments for mental health issues.
“I see my work with Genomind and the book intersecting in an important way.…Both focus on how understanding our brains better can relieve suffering,” says Lombard. “I believe in the compatibility of science and faith.…My clinical background is a portal through which to better understand the complicated human experience.”
Lombard helped create Genomind because he thought mapping the human genome could provide important new clues to treating those with mental health challenges, a sector that has lagged behind others in terms of medical advancements using personalized medicine.
The book’s foreword is written by Rep. Patrick Kennedy, who serves as a special advisor to Genomind. He writes, “Our mission is to collaborate, cooperate and otherwise come together, not only to research causes and treatments to brain ailments but to prevent them from occurring in the first place.”
Deepak Chopra, MD, New York Times bestselling author of “How to Know God” says, “’The Mind of God’ is inspiring, insightful and thought provoking. This book will awaken new connections in our understanding of the exhilarating relationship between reality, reason and faith.”
Booklist’s review says, “Contextualizing scientific precepts with humanizing personal accounts of psychiatric patients — and family members — Lombard erects a much-needed bridge between science and faith.”
The Genecept Assay is in use by clinicians in all 50 states; it now covers more than 20 drug classes, 122 medications approved by the U.S. Food and Drug Administration, 18 clinically validated genes and 97 percent of medications used to treat depression, anxiety, bipolar disorder, schizophrenia, attention-deficit disorder and autism. It also offers comprehensive coverage of pain medications.
Genomind is a personalized medicine company bringing innovation to mental health care through genetic testing. Genomind is comprised of pioneering researchers and thought leaders in psychiatry and neurology and specializes in pharmacogenetic laboratory testing for psychiatry. Genomind is committed to partnering with clinicians to improve their patients’ lives. Learn more at www.genomind.com.
About the Genecept Assay
The Genecept Assay is a genetic test designed to help clinicians optimize treatment decisions for their patients with mental illness. It identifies patient-specific genetic markers that indicate which treatments are likely to work as intended, have no effect or cause adverse effects. It is an easily administered cheek swab test that analyzes key genes that have been selected based on hundreds of studies showing that variations in these genes can inform treatment decisions. The Assay is used to guide treatment for a range of psychiatric conditions, including depression, anxiety, obsessive-compulsive disorder (OCD), attention-deficit hyperactivity disorder (ADHD), bipolar disorder, post-traumatic stress disorder (PTSD), autism, schizophrenia, chronic pain and substance abuse, and has been shown in peer-reviewed published studies to improve patient outcomes and reduce overall medical costs. Each Assay provides clinicians with an easy-to-read patient report and a complimentary psychopharmacogenomic consultation. Learn more at www.genomind.com
Vice President, Marketing and Corporate Communications